Thrombopoietic activity of recombinant human interleukin-11 in nonhuman primates with ACNU-induced thrombocytopenia
| Autor: | M, Saitoh, K, Taguchi, S, Yasuda, M, Kikumori, T, Nishimori, M, Suda, H, Okamiya, S, Usuda, K, Miyata |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Male
medicine.medical_specialty Anemia Immunology Antineoplastic Agents law.invention chemistry.chemical_compound Leukocyte Count law Bone Marrow Virology Internal medicine medicine Animals Humans Platelet Leukopenia business.industry Platelet Count Nimustine Cell Biology medicine.disease Interleukin-11 Thrombocytopenia Severe thrombocytopenia Recombinant Proteins Hematopoiesis Interleukin 11 Macaca fascicularis Endocrinology chemistry Recombinant DNA Erythrocyte Count Bone marrow megakaryocytes medicine.symptom business |
| Zdroj: | Journal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research. 20(6) |
| ISSN: | 1079-9907 |
| Popis: | The effect of recombinant human interleukin-11 (rHuIL-11) on myelosuppressive nimustine (ACNU)-induced thrombocytopenia was assessed in nonhuman primates. A single intravenous (i.v.) injection of ACNU (15 mg/kg) was administered to cynomolgus monkeys on day 0. rHuIL-11 (100 microg/kg/day) or the vehicle was given subcutaneously (s.c.) from day 1 to day 21. In monkeys receiving ACNU, the circulating platelet count decreased to a low of 42 +/- 6 x 10(9)/L by day 21 but returned to pretreatment levels (375 +/- 48 x 10(9)/L) on day 30. Administration of rHuIL-11 prevented severe thrombocytopenia; the platelet count fell only to 138 +/- 23 x 10(9)/L on day 18, and platelet recovery was faster (458 +/- 91 x 10(9)/L by day 27) compared with that of the control animals. The size of bone marrow megakaryocytes from rHuIL-11-treated animals was larger than that of the controls, indicating that rHuIL-11 stimulated megakaryopoiesis in a myelosuppressive condition. Treatment with ACNU also caused leukopenia and moderate anemia. rHuIL-11 transiently and slightly decreased the white blood cell (WBC) and red blood cell (RBC) counts. Conversely, rHuIL-11 accelerated recovery of RBC count in the late administration period. These results support the assertion that rHuIL-11 may be an important therapeutic agent for reducing the severity and duration of thrombocytopenia following cancer chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|